As Per the Report, the Europe Mycoplasma Testing Market Size is valued at USD 179.72 Million in 2023 and is estimated to be growing at a CAGR of 12.6%, to reach USD 325.30 Million by 2028 during the forecast period 2023 to 2028.
The growth of the Europe mycoplasma testing market is driven by various factors such as increasing concerns over cross-contamination of cell cultures, growth of pharmaceutical &biotechnology industries, and increasing major pharmaceutical R&D activities and public-private investments.
Contamination of cell cultures is one of the common problems encountered in cell culture laboratories. These cell culture contaminants categories basically involve either chemical contaminants or biological contaminants. Chemical contaminants such as impurities in culture media, serums, water, endotoxins, plasticizers samples and detergents, while biological contaminants includes bacteria, molds, yeasts, viruses and mycoplasmas as contamination crossed by other cellular microorganisms. For the detection of such contaminations, various tests are used, including the mycoplasma test. Various funds and grants help drive the market growth.
The high cost of the instruments along with lab maintenance acts as a restraint for mycoplasma testing in the growing European mycoplasma testing market.
The main reasons why pharmaceutical and biopharmaceutical companies choose to outsource R&D and clinical trials are cost effectiveness, ease of patient recruitment, lower operating costs and less stringent regulatory frameworks than in other nations. In addition to reducing costs, sponsors attribute improved quality and reduced time to market as the main drivers of outsourcing their business functions to CROs, CDMOs and CMOs. As a result, many pharmaceutical and biotechnology companies and academic institutes choose to outsource functions such as manufacturing, clinical trial management, R&D, and drug discovery to CROs. These provide opportunities for market to develop.
The main companies in this market are large and well established and enjoy a high degree of brand loyalty. Newly developed products in the European mycoplasma testing market compete with existing testing kits and distinguish themselves by developing innovative product offers. The high degree of consolidation is a major barrier to entry for new entrants, which in turn should restrict investments and therefore slow the growth potential of this market.
This research report on the Europe Mycoplasma Testing Market has been segmented and sub-segmented into the following categories
Germany dominates the European market due to the growing demand for efficient testing.
The Germany Mycoplasma Testing Market is growing due to the high rate of adoption of new technologies and the large number of life science research studies conducted in this region, while the UK Mycoplasma Testing Market is expected to grow at the rate of growth over the forecast period of 2023 to 2028 due to significant outreach and funding initiatives generated by countries like India. The European government are undertaking several strategic initiatives to facilitate additional R&D activities for the introduction of new drugs.
Other regions have a lesser share in the European market comparatively to those of developed nations such as Spain, Italy, France and Sweden etc., this can be attributed mainly to the lesser growth of the biotechnology and pharmaceutical industries, the increasing rate of adoption of new technologies and the large number of life science research studies conducted in these regions.
Prominent Companies dominating the Europe Mycoplasma Testing Market Profiled in the Report are PromoCell GmbH, Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Lonza Group Ltd., Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, WuXi AppTec.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com